Jason Ryan has hopped from Foundation to Medicine to Magenta Therapeutics after playing a key role in Foundation’s $2.4 billion buyout by Roche.

Results from Aimmune’s phase 3 trial of AR101 for peanut allergy have been published and bode well for its planned FDA filing next month.

The Forbion-led series B tees up Inflazome to trial its NLRP3 inflammasome inhibitors in several inflammatory diseases.

The deal gives the Roche subsidiary at least a partial stake in the preclinical MAGE-A4-targeting drug IMC-C103C.

Neurodegenerative disease startup QurAlis has extended the seed round it first announced in April, bringing its total funding up to $5.5 million.

Johnson & Johnson Vision inked a $26.35 million collaboration with the Singapore Eye Research institute focused on treating nearsightedness.

Antimalarial drugs known as chloroquines play a role in inhibiting cancer cell growth by targeting the enzyme PPT1, researchers discovered.

Camel-IDS will run a phase 1b/2 trial of its lead radiopharmaceutical in HER2-positive breast cancer that has spread to the brain.

WuXi AppTec opened a new medical device testing facility just outside Shanghai in Suzhou, China.